Kornimate/medical-research-clean huggingface dataset:
change in c-reactive protein (crp) in men and women with sleep apnea after continuous positive airway pressure (cpap)

Conditions: Obstructive Sleep Apnea

Summary: c-reactive protein (crp) is directly implicated in atherogenesis and associated cardiovascular morbidity in patients with obstructive sleep apnea (osa). effective continuous positive airway pressure (cpap) treatment has been shown to gradually decrease crp levels and thus consequently improve disease-related cardiovascular morbidity. however, the influence of gender on the crp evolution pattern has never been assessed before. the aim of our study was to investigate possible gender differences in crp evolution in osa patients 3 and 6 months after the start of effective cpap treatment.

osa is an independent risk factor for a number of cardiovascular diseases. one important possible mechanism underlying cardiovascular disease in patients with osa is systemic inflammation. crp, an acute phase reactant secreted by the liver, is one of the most actively studied biomarkers of low-grade inflammation, and numerous studies have shown that higher crp levels are associated with high mortality and morbidity due to cardiovascular disease in men and women. in patients with osa, the question as to whether or not crp levels are elevated is still under debate. although continuous positive airway pressure (cpap) is effective in the management of osa, conflicting data also exist regarding the effects of cpap on crp levels. however, none of the existing studies assessed the influence of gender on the crp evolution pattern. therefore, the aim of this study was to investigate possible gender differences in crp evolution in patients with moderate to severe osa, free of medical comorbidities, 3 and 6 months after the start of effective cpap treatment.

Eligibility criteria:
inclusion criteria: * patients with apnoea-hypopnoea index \>15/h exclusion criteria: * chronic obstructive pulmonary disease * diabetes mellitus * coronary artery disease * congestive heart failure * chronic renal failure * known dyslipidemia * smoking history * hypothyroidism * chronic or recent infectious or inflammatory disease * use of anti-inflammatory or antibiotic drugs, or statins. * postmenopausal females on estrogen replacement therapy.
role of fibrocytes in chronic obstructive pulmonary disease

Conditions: Chronic Obstructive Pulmonary Disease

Summary: chronic obstructive pulmonary disease (copd) is a frequent airway disease characterized by both bronchial inflammation and remodelling. bronchial mucosa is infiltrated by macrophages, neutrophils and lymphocytes. in addition, the number of eosinophils can be also increased during exacerbation. airway remodelling is an abnormal tissue repair following bronchial inflammation, which contributes to none reversible pathological features, such as bronchial and peri-bronchial fibrosis. it also influences the prognosis of copd and its mechanisms remain largely unknown. the role of fibrocytes has been demonstrated in the pathophysiology of asthma, lung fibrosis or pulmonary hypertension. however, the recruitment of blood fibrocytes and their involvement in copd airway remodelling remain unknown.


Eligibility criteria:
inclusion criteria: * patients: diagnostic of chronic obstructive pulmonary disease (copd) exacerbation. * control group: subjects without any history of lung disease and with normal lung function testing. subjects will be separated in 2 sub-groups according to smoking history (never smokers, smokers (former or current) and paired to patients according to age and sex. * written informed consent exclusion criteria: * subject without any social security or health insurance * asthma, lung fibrosis or idiopathic pulmonary hypertension * chronic viral infections (hepatitis, hiv)
a trial comparing transnasal humidiﬁed rapid insufﬂation ventilatory exchange (thrive) and apneic oxygenation with facemask ventilation in elderly patients undergoing induction of anaesthesia.

Conditions: Anesthesia Intubation Complication; Postoperative Complications

Summary: induction of general anaesthesia in patients undergoing emergency surgery can be challenging, because of the often suboptimal circumstances under which anaesthesia has to be delivered, as well as potential physiological derangements caused by their underlying illness, especially in elderly patients. pre-oxygenation is usually achieved using oxygen delivered via a facemask before induction of anaesthesia. in patients undergoing elective surgery, the lungs are normally ventilated with a bag/facemask technique after induction. however, these options for oxygenation are limited. facemask ventilation has a perceived risk of gastric insufflation of gas, leading to increased intragastric pressure and raised risk of pulmonary aspiration of stomach contents. nasal cannulae have been recommended as an alternative method of delivering continuous oxygen during induction of anaesthesia. the aim of this study is to compare the effect of transnasal humidified rapid insufflation ventilatory exchange (thrive) oxygenation with facemask oxygenation on extended apnoeic period and postoperative respiratory complications in elderly patients undergoing induction of anaesthesia.


Eligibility criteria:
inclusion criteria: * patients who required induction of general anaesthesia for emergency surgery, whose routine clinical care required arterial blood gas sampling, and who were competent to give consent were recruited. exclusion criteria: * patients who had severe respiratory disease.
evaluation of the sensitivity to different chemotherapy regimens in platinum-partial sensitive recurrent ovarian cancer

Conditions: Ovarian Cancer

Summary: multicenter, prospective, randomized studies.evaluation of the sensitivity to different chemotherapy regimens in platinum-partial sensitive recurrent ovarian cancer based on 11 gene tests of homologous recombination pathway.

patients meeting the following inclusion criteria were randomly divided into two groups in a 1:1 ratio: paclitaxel/platinum chemotherapy group (tp) and doxorubicin hydrochloride liposome injection/platinum chemotherapy group (pp) (the specific chemotherapy regimens are as follows.chemotherapy to tumor progression or adverse reactions can not be tolerated, effective chemotherapy patients with a maximum of 6 cycles of chemotherapy.the primary endpoint was progression-free survival (pfs), and the secondary endpoints were safety and overall survival.also uses the next-generation sequencing (ngs) method to detect patients with recurrence after tumor tissues (including chest, ascites, homologous recombination pathway in the tumor tissue and peripheral blood ctdna 11 genetic mutations, rearrangement, and so on and so forth, whether patients with analysing the homologous recombination pathways for paclitaxel/platinum chemotherapy or doxorubicin hydrochloride liposome injection/platinum chemotherapy has different sensitivity.

Eligibility criteria:
inclusion criteria: 1. age: 18-75 years old 2. ps score: ecog 0 \~ 2 3. histopathologically confirmed primary high-grade serous adenocarcinoma or high-grade endometrioid adenocarcinoma of the ovary, fallopian tube or peritoneum; 4. the time interval between this recurrence and the last chemotherapy was 6-12 months; 5. evaluate the ability of bone marrow, liver, kidney, heart and other important organ functions to withstand chemotherapy; 6. expected survival over 3 months; 7. sign the informed consent. exclusion criteria: 1. brain metastasis or the presence of symptoms caused by brain metastasis; 2. serious complications; 3. acute inflammatory reaction; 4. other tumors; 5. a history of allergy to paclitaxel or polyropyridone liposomes;
hypofractionated pencil-beam scanning intensity-modulated proton therapy (impt) in recurrent rectal cancer

Conditions: Recurrent Rectal Cancer

Summary: the purpose of this trial is to determine the maximum tolerated dose (mtd) of hypofractionated impt for the reirradiation of locoregionally recurrent rectal cancer.


Eligibility criteria:
inclusion criteria: * history of biopsy-proven adenocarcinoma of the rectum, anus or rectosigmoid junction of any stage now with recurrent disease in the pelvis * one prior course of radiation therapy to the pelvis for rectal cancer * ecog performance status 0-2 * at least 18 years of age * women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control, abstinence) prior to study entry and for the duration of study participation. should a woman become pregnant or suspect she is pregnant while participating in this study, she must inform her treating physician immediately. * able to understand and willing to sign an irb-approved written informed consent document. exclusion criteria: * patients with pre-existing radiosensitizing conditions, such as connective tissue disorders (i.e. lupus, scleroderma) and genetic mutations (i.e. ataxia-telangiectasia) * a history of other malignancy with the exception of malignancies for which all treatment was completed at least 2 years before registration and the patient has no evidence of disease, basal cell or squamous cell carcinoma of the skin that were treated with local resection only, or carcinoma in situ of the cervix. patients with history of prostate cancer treated without radiotherapy and no evidence of disease are eligible * more than one prior course of radiation to the pelvis for rectal cancer * prior radiation to the pelvis for disease other than rectal cancer * tumor in the rectum/colon requiring radiation therapy to the full circumference of the rectum/colon. * current treatment with any investigational agents. * uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, or unstable angina pectoris * pregnant and/or breastfeeding. women of childbearing potential must have a negative urine or serum pregnancy test within 14 days of study entry.
the efficacy of alirocumab for thin-cap fibroatheroma in patients with coronary artery disease estimated by optical coherence tomography

Conditions: Coronary Artery Disease; Thin-cap fIbroatheroma

Summary: the purpose of this study is to show that alirocumab with statin therapy have a s tronger stabilizing effect on vulnerable plaque in coronary artery disease than statin alone administration

the investigators investigate to evaluate the efficacy of alirocumab for vulnerable plaque. the investigators enrolled the patient with standard statin therapy who were detected vulnerable plaque by optical coherence tomography, and categorized into two group; the patients with alirocumab and rosuvastatin were categorized alirocumab therapy group, and the patients with rosuvastatin alone were categorized standard statin therapy group. the investigators compare these two group for outcomes.

Eligibility criteria:
inclusion criteria: 1. patients who underwent pci for acs or stable coronary heart disease 2. patients with ldl-c ≥70 mg/dl under daily 10mg rosuvastatin 3. patients who have been had tcfa detected by oct 4. patients aged ≥20 years old at pci 5. patients who agree to be enrolled in the trial giving signed written informed consent exclusion criteria: 1. patients who have been treated previously with at least one dose of any anti-pcsk9 monoclonal antibody 2. patients had uncontrolled hypertension (systolic blood pressure \>180 mmhg or diastolic blood pressure \>110 mmhg) between the time of pci and randomization visit 3. known hypersensitivity to alirocumab or rosuvastatin 4. all contraindications to alirocumab and/or rosuvastatin as displayed in the respective national product labeling for these treatments 5. known history of hemorrhagic stroke 6. currently under treatment for cancer 7. patients on lipoprotein apheresis 8. patients with severe liver or renal dysfunction 9. pregnant or breast-feeding women 10. considered by the investigator as inappropriate for this study for any reason

Keywords: alirocumab thin-cap fibroatheroma (tcfa) vulnerable plaque optical coherence tomography (oct)
effects of dexmedetomidine on stress response and postoperative analgesia

Conditions: Restlessness; Pain

Summary: dexmedetomidine is a highly selective α2 adrenoreceptor agonist approved by the us fda for short-term postoperative sedation and analgesia.it can also reduce the stress response without respiratory depression. in this prospective, randomized, double-blind, placebo-controlled study，we gave dexmedetomidine or saline placebo 1h before operations were over and assessed the effects of dexmedetomidine on stress response and postoperative analgesia in patients undergoing thoracotomy during anesthesia recovery period.

dexmedetomidine can significantly reduce the emergence agitation and postoperative pain in patients who received chest surgery

Eligibility criteria:
inclusion criteria: * american society of anaesthesiologists physical status (asa-ps) i or ii * undergoing selective thoracotomy * weight between 45 and 75kg * operation time 2-4 hours exclusion criteria: * history of neurologic disease * history of chronic analgesics intake * history of allergic reactions to the experimental durgs * history of renal insufficiency * history of hepatic dysfunction * history of coagulation disorders * women in lactation * participating in other studies
effects of aloe vera toothpaste on periodontal parameters

Conditions: Gingivitis

Summary: this study aimed to assess the effects of aloe vera toothpaste on dental plaque and gingivitis. the single-blind cross-over clinical trial was conducted on 20 dental students (10 males and 10 females with a mean age of 24.5±4 yrs.) with gingivitis. students were randomly divided into 2 groups. the first group used aloe vera toothpaste for 30 days. a 2-week wash-out period was allowed and then subjects used fluoride toothpaste for the next 30 days . this order was reversed in group 2.

toothpastes are used with tooth brushing to better control microbial plaque. herbal toothpastes have recently gained attention. this study aimed to assess the effects of aloe vera toothpaste on dental plaque and gingivitis. this single-blind cross-over clinical trial was conducted on 20 dental students (10 males and 10 females with a mean age of 24.5±4 yrs.) with gingivitis. students were randomly divided into 2 groups. the first group used aloe vera toothpaste for 30 days and then their plaque index (pi) and gingival index (gi) were recorded. a 2-week wash-out period was allowed and then subjects used fluoride toothpaste for the next 30 days and underwent pi and gi assessment again. this order was reversed in group 2. wilcoxon-sign rank and two way repeated measure anova tests were applied for statistical analysis.

Eligibility criteria:
inclusion criteria: * subjects were selected among dental students with at least 20 natural teeth without systemic disease * no periodontal treatment at least 6 months to the study * no use of systemic antibiotic and anti-inflammatory drugs within the last 3 months, nonsmokers, no pregnancy or lactating women * subjects with pd≤3mm, (clinical attachment level)cal\<1mm, pi≥2 and gingival bleeding in more than 30% of the tested areas were enrolled with the diagnosis of plaque-related gingivitis. exclusion criteria: * subjects with orthodontic appliances ,multiple bridges, partial denture, multiple caries were excluded from the study

Keywords: clinical trial oral hygiene gingivitis aloevera toothpaste anti-inflammatory agents
modeling of intracerebral vascularization after extracorporeal membrane oxygenation in children

Conditions: Extra Corporeal Membrane Oxygenation; Decanulated Alive

Summary: extra corporeal membrane oxygenation (ecmo) is a transient supplementation technique that alleviates hemodynamic and ventilatory failure. its implementation requires carotid arterial and jugular venous cannulation in newborns or children weighing less than 20 kg. the impact of ecmo on arterial circulation was studied by doppler ultrasound and shows a redistribution of flows within the circle of willis. this study aims to model cerebral flow in children who have been cared from jugulocarotid ecmo and compare cerebral hemodynamics according to the technique of reconstruction of the common carotid artery after decanulation (reconstruction or ligation).

extra corporeal membrane oxygenation (ecmo) is a transient supplementation technique that alleviates hemodynamic and ventilatory failure. its implementation requires carotid arterial and jugular venous cannulation in newborns or children weighing less than 20 kg. the impact of ecmo on arterial circulation was studied by doppler ultrasound and shows a redistribution of flows within the circle of willis. when ecmo is stopped, carotid decanulation is done either by ligation or by reconstruction, depending on the practices of the surgical team and the peroperative findings. the reconstruction allows a restoration of blood flow to the internal carotid artery and the middle cerebral artery with a disappearance of compensation by the circle of willis. vascular flow modeling is a computational method derived from imaging for the hemodynamic study of fluids, including pressures and flow rates at different points in a vessel. data from the literature on the modeling of cerebral vascularization in newborns are scarce. this study aims to model cerebral flow in children who have been cared from jugulocarotid ecmo and compare cerebral hemodynamics according to the technique of reconstruction of the common carotid artery after decanulation (reconstruction or ligation).

Eligibility criteria:
inclusion criteria: for everyone : 1. information and non-opposition of holders of parental authority 2. newborn, infant and child \<20kg 3. hospitalization in pediatric and neonatal intensive care unit (picu) of trousseau hospital 4. performing a magnetic resonance angiography (mra) as part of the treatment for patients treated with ecmo: study population 5. hemodynamic or respiratory failure 6. requiring the use of extracorporeal circulation with jugulo-carotid cannulation 7. weaned alive off extra corporeal membrane oxygenation (ecmo) for patients with hypoxic-ischemic encephalopathy: control population 8. hypoxic-ischemic encephalopathy diagnosed at birth exclusion criteria: 1. contraindication to mra 2. opposition of holders of parental authority

Keywords: extra corporeal membrane oxygenation pediatric patients arterial circulation techniques of carotid decanulation circle of willis magnetic resonance angiography
long-term survivorship of discharged patients with malignant tumor based on single-institutional cancer registry

Conditions: Neoplasms; Survival; Surgery; Radiotherapy; Drug Therapy

Summary: real-world studies on long-term prognosis in patients who underwent anti-tumor treatments during hospitalization from a hospital-based cancer registry in china.

this is a single-center continuous enrollment cohort study. the overall survival and disease-free survival of patients with malignant tumors in the target tumor hospital undergoing surgery, radiotherapy, chemotherapy, and immunotherapy were observed. follow-up methods include medical records review, telephone call interview, and data linkage to the related provincial death certificate registries. this study will provide real world data-sets for researches on long-term survival and prognosis of cancer patients, and expend exploration on the cancer survival determinants both from clinical and social-economic prospective.

Eligibility criteria:
inclusion criteria: * all patients who completed tumor treatment (including surgery, radiotherapy, chemotherapy, immunotherapy, etc.) due to malignant tumors based on preoperative or intraoperative evaluation in fudan university shanghai cancer center during the study period. exclusion criteria: * patients who have not been treated during hospitalization; * patients with non-malignant tumors.

Keywords: cancer survivorship
identification by transcriptomic approach of new prognostic and predictive markers in a cohort of atypical meningiomas

Conditions: Meningioma Atypical

Summary: determine by a transcriptomic approach new prognostic and predictive markers in atypical meningiomas (who grade ii). retrospective observational study, on a cohort of 85 atypical meningiomas. transcriptomic study first, on cryopreserved tumor samples. then identify, thanks to the transcriptomic study, prognostic and predictive factors (study of the link between the quantity of certain rna transcripts and progression-free survival). finally, set up immunohistochemical applications, which can be used routinely by the pathologist.


Eligibility criteria:
inclusion criteria: * primary operated patients for an atypical meningioma (who grade ii) in the neurosurgery department of the university hospital of nancy. * at least one postoperative follow-up visit. * adult patients (\>18 yo) at the time of the intervention. * surgical excision. exclusion criteria: * history of meningioma in the same location. * neo-adjuvant treatment. * absence of non-objection form.

Keywords: transcriptome
registry to assess the safety and feasibility of the subpulmonary support with the novel venous cannula in patients with failing/absence of the right heart

Conditions: Heart Failure; Univentricular Heart; Ventricular Dysfunction; Heart Diseases; Cardiovascular Diseases

Summary: the purpose of the study is to monitor the clinical safety and performance of the excor venous cannula in context of an excor vad therapy to ensure continued acceptability of identified risks, to enable detecting emerging risks and to assess clinical improvement on both short- and long-term.

the registry study has an observational, prospective, international, multi-center, non-randomized design. the registry is planned for 42 months (3.5 years), with an enrollment period of 28 months, the follow-up of up to 12 months.

Eligibility criteria:
inclusion criteria: * patient or his/her parent/guardian or legally authorized representative has given the consent by means of a written, signed and dated informed consent form, * the indications on rvad and bvad use of the excor vad apply, * patient shall be on transplant list or at least eligible for htx, * bsa (body surface area) greater than or equal to 1.2 m². exclusion criteria: * patient or his/her parents/legal guardian or legally authorized guardian has not given the consent, * the contraindications of excor vad apply.

Keywords: excor ventricular assist device excor venous cannula failing fontan